Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q− MDS (IPSS low and intermediate-1)-Reference-Cited by-同舟云学术

Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q− MDS (IPSS low and intermediate-1)

Published:2012-12 Issue:12 Volume:36 Page:e222-e224
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Jonasova Anna,Cermak Jaroslav,Vondrakova Jana,Siskova Magda,Hochova Ivana,Kadlckova Eva,Cerna Olga,Sykora Michal,Vozobulova Vera,Seifertova Nadezda,Michalova Kyra,Zemanova Zuzana,Brezinova Jana,Belohlavkova Petra,Kostecka Arnost,Neuwirtova Radana

Funder

Czech research grant

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference5 articles.

1. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31;Giagounidis;Leukemia,2004

2. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q;Mallo;Leukemia,2011

3. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome;Gonzalez-Porras;Cancer,2011

4. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications;Al Ameri;Clin Lymphoma Myeloma Leuk,2011

5. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression;Jädersten;J Clin Oncol,2011

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs;Cardiovascular & Hematological Disorders-Drug Targets;2019-01-28

2. Lenalidomide treatment in lower risk myelodysplastic syndromes—The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients);Leukemia Research;2018-06

3. TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes;Oncotarget;2016-05-06

4. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis;Leukemia Research;2014-03

5. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations;British Journal of Haematology;2013-04-25